[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100197289":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":41,"centralContacts":33,"locations":45,"responsibleParty":59,"collaborators":33,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":33,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":33,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":33,"overallStatus":81,"whyStopped":33,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A","ACTIVE_COMPARATOR","treatment A, reference, 20 micron palbociclib and lubrication level 1",[13],"Other: Palbociclib Formulation Reference",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment B","treatment B, test, 50 micron palbociclib and lubrication level 1",[18],"Other: Palbociclib Formulation Test",{"label":20,"type":10,"description":21,"interventionNames":22},"Treatment C","treatment C, test, 20 micron palbociclib and lubrication level 2",[18],{"label":24,"type":10,"description":25,"interventionNames":26},"Treatment D","treatment D, test, 20 micron palbociclib and lubrication level 3",[18],[28,34,37,39],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"OTHER","Palbociclib Formulation Reference","Single 45 mg dose; Dosage form is capsule taken orally.",[9],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"Palbociclib Formulation Test",[15],{"type":29,"name":35,"description":31,"armGroupLabels":38,"otherNames":33},[20],{"type":29,"name":35,"description":31,"armGroupLabels":40,"otherNames":33},[24],[42],{"name":43,"affiliation":5,"role":44},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[46],{"facility":47,"status":33,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":33},"Pfizer Investigational Site","New Haven","Connecticut","06511","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-72.92816,41.30815,{"lat":57,"lon":56},{"type":60,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100197289","phase-1-a-study-in-healthy-volunteers-to-estimate-the-effect-of-the-active-ingredient-particle-size-and-percentage-of-the-excipients-used-to-formulate-the-capsules-in-the-dissolution-rate-of-the-formulations-in-the-gastrointestinal-tract-100197289",false,"NCT01844323","A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract","A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study In Healthy Volunteers To Estimate The Effect Of Active Pharmaceutical Ingredient Particle Size And Lubrication On The Bioavailability Of A Single 125 Mg Dose Of Palbociclib (PD-0332991) Administered Under Fasted Conditions","Inclusion Criteria:\n\n* Healthy male subjects and\u002For female subjects with no physical possibility of getting pregnant.\n* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.\n* Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.\n* Any condition possibly affecting drug absorption (eg, gastrectomy).\n* A positive urine drug screen.\n* History of regular alcohol consumption exceeding 7 drinks\u002Fweek for females or 14 drinks\u002Fweek for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.\n* Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) preceding the first dose of study medication.\n* Pregnant females; breastfeeding females; females with physical possibility of getting pregnant .",true,"ALL","18 Years","55 Years",{"count":73,"type":74},24,"ACTUAL","INTERVENTIONAL",[77],"PHASE1","The particle size of the active ingredient may impact dissolution rate in the gastro intestinal tract and hence the amount of drug available for absorption. Similarly, differences in the percentage of the excipients used in the formulated capsules may affect dissolution rate. The purpose of this study is to estimate the effect that particle size and percentage of excipients could have in drug absorption, which will improve the manufacturing process of the formulated capsules.",[80],"Healthy","COMPLETED","2013-08-27",{"date":84,"type":85},"2013-08-28","ESTIMATED",{"date":87,"type":33},"2013-06",{"date":89,"type":74},"2013-08",{"name":5,"class":6},1]